» Articles » PMID: 31782025

Nonalcoholic Fatty Liver Disease As a Risk Factor for Clostridioides Difficile Infection

Overview
Publisher Springer
Date 2019 Nov 30
PMID 31782025
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea while nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The aim of this study was to determine whether NAFLD increases susceptibility to CDI. A retrospective cohort study included patients ≥ 65 years, treated with antimicrobial therapy ≥ 24 h, and hospitalized ≥ 72 h in a 36-month period. Three-hundred fourteen patients were included; 83 with NAFLD and 231 controls. Except for diabetes mellitus (37.35% vs. 25.11%, p = 0.0462) and obesity (18.07% vs. 8.23%, p = 0.0218) that were more frequent in NAFLD group, there were no differences in other comorbidities, hospital admissions, antibiotic therapy within 3 months, prescription, and duration of antibiotic therapy. Fourteen (16.9%) patients with NAFLD and 17 (7.4%) in control group developed in-hospital CDI (p = 0.0156). The Charlson Age-Comorbidity Index > 6 (OR 4.34, 95%CI 1.39-13.57), hospital admission within 3 months (OR 7.14, 95%CI 2.33-21.83), serum albumins < 28 g/L (OR 3.15, 95%CI 1.04-9.53), NAFLD (OR 3.27, 95%CI 1.04-10.35), eGFR < 40 (OR 4.89, 95%CI 1.61-14.88), treatment with piperacillin/tazobactam (OR 4.86, 95%CI 1.59-14.83), and carbapenems (OR 3.99, 95%CI 1.28-12.40) were independently associated with CDI. Our study identified NAFLD as an independent predictor of CDI.

Citing Articles

The Impact of Steatotic Liver Disease on Cytokine and Chemokine Kinetics During Sepsis.

Vrsaljko N, Radmanic Matotek L, Zidovec-Lepej S, Vince A, Papic N Int J Mol Sci. 2025; 26(5).

PMID: 40076848 PMC: 11900930. DOI: 10.3390/ijms26052226.


Nonalcoholic Fatty Liver Disease Increases the Risk of Lung Abscess: Findings from a Nationwide Cohort Study.

Lee E, Kim J, Yoon S J Clin Med. 2025; 14(2).

PMID: 39860549 PMC: 11765748. DOI: 10.3390/jcm14020542.


Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis.

Mantovani A, Morandin R, Fiorio V, Lando M, Gaviraghi A, Motta L Liver Int. 2024; 45(4):e16101.

PMID: 39258758 PMC: 11892334. DOI: 10.1111/liv.16101.


Steatotic Liver Disease and Sepsis Outcomes-A Prospective Cohort Study (SepsisFAT).

Krznaric J, Papic N, Vrsaljko N, Gjurasin B, Kutlesa M, Vince A J Clin Med. 2024; 13(3).

PMID: 38337491 PMC: 10856507. DOI: 10.3390/jcm13030798.


infection in patients with nonalcoholic fatty liver disease-current status.

Kiseleva Y, Maslennikov R, Gadzhiakhmedova A, Zharikova T, Kalinin D, Zharikov Y World J Hepatol. 2023; 15(2):208-215.

PMID: 36926243 PMC: 10011916. DOI: 10.4254/wjh.v15.i2.208.


References
1.
Mulki R, Baumann A, Alnabelsi T, Sandhu N, Alhamshari Y, Wheeler D . Body mass index greater than 35 is associated with severe Clostridium difficile infection. Aliment Pharmacol Ther. 2016; 45(1):75-81. DOI: 10.1111/apt.13832. View

2.
Papic N, Stemberger Maric L, Vince A . Efficacy of oral vancomycin in primary prevention of Clostridium Difficile infection in elderly patients treated with systemic antibiotic therapy. Infect Dis (Lond). 2018; 50(6):483-486. DOI: 10.1080/23744235.2018.1425551. View

3.
Magill S, Edwards J, Bamberg W, Beldavs Z, Dumyati G, Kainer M . Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014; 370(13):1198-208. PMC: 4648343. DOI: 10.1056/NEJMoa1306801. View

4.
Mullane K, Winston D, Nooka A, Morris M, Stiff P, Dugan M . A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2018; 68(2):196-203. PMC: 6321849. DOI: 10.1093/cid/ciy484. View

5.
Crobach M, Planche T, Eckert C, Barbut F, Terveer E, Dekkers O . European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016; 22 Suppl 4:S63-81. DOI: 10.1016/j.cmi.2016.03.010. View